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and intravenous enoxaparin (30 mg) followed by angiography within 3-12 hs of randomis-
ation and adequate revascularisation (culprit artery plus non-culprit severe diseased
arteries threatening functionally important areas) with stenting or surgery. When T failed
(TIMI flow grade 0 or 1) abciximab was given before stenting. Heparin was stopped in
both groups after PCI. The co-primary endpoints were: infarct size (CK-MB mass, cTnT
release), left ventricle 6-week angiographic evolution (volume, ejection fraction, wall
motion index) and myocardial reperfusion (normalization of ST at 3 and 6 hs). The inci-
dence of cardiac and non-cardiac events was also compared.
Results: There were no differences between primary PCI and facilitated strategies in
terms of infarct size (CK-MB mass: 4768±3734 vs 4602±3371 ug/Lxh, p= 0.76; cTnT:
275±211 vs 242±156 ug/Lxh, p=0.55), left ventricular ejection fraction at 6 weeks (56±13
vs 56±12%, p= 0.9); wall motion index at six weeks (-1.1±0.6 vs -1.2±0.4, p= 0.1) and
myocardial perfusion (normalization of ST at 3 hs: 47 vs 46%, p= 0.83). However, in facil-
itated pts the incidence of complete ST resolution at 6 hs was higher (43 vs 61%,
p=0.03), and the rate of cardiac events at six month tends to be lower (death, reinfarction
or revascularization: 14% vs 9%).
Conclusions: According to the results of the GRACIA-2 trial, the strategy of performing
facilitated intervention is as safe as optimal primary PCI for pts with STEAMI. Results
also suggest that both strategies have equivalent efficacy in restoring myocardial perfu-
sion, preserving left ventricular size and function and beneficing clinical outcome.
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Background: In the setting of severe, flow-limiting coronary artery stenosis, we have
previously shown that drag-reducing polymers (DRPs), which are unique, blood-soluble
macromolecules, have therapeutic potential because they further lower microvascular
resistance and enhance perfusion, even after autoregulation is exhausted. In bench stud-
ies involving rigid tubes, DRPs reduce resistance by altering the hydrodynamic proper-
ties of blood flow. Whether changing blood rheology is their mechanism of action in vivo,
or whether it also involves vasodilation is unclear. To test the hypothesis that DRPs
decrease resistance and increase blood flow without causing vasodilation, we examined
the microcirculation of the cremaster muscle in rats using intravital microscopy. Methods:
Catheters were placed in the carotid artery for pressure measurement in 13 anesthetized
rats. A flow probe was placed around the abdominal aorta. The cremaster muscle was
exposed and mounted on a microscope. Red blood cell (RBC) velocity and vessel diame-
ters were measured in arterioles (A), venules (V), and capillaries (C) pre- and post- intra-
venous DRP (polyethylene oxide, 1PPM). Vascular resistance was calculated as mean
arterial pressure/aortic flow. In 5 controls, topical nipride was applied to the cremaster to
confirm measurable vasoactivity in our model. Results: Arteriolar diameter increased
18±4% (p<0.03) after topical nipride in controls. DRP increased aortic flow (7.4±1.0 vs.
5.0±0.6 mL/min, p<0.002) and decreased vascular resistance (14.2±1.7 vs. 23.5±2.7
mmHg-min/mL, p<0.01). There was no significant change in diameter at any microvascu-
lar level in association with this resistance reduction. DRP increased RBC velocity in the
A (13.0±0.8 vs. 11.4±0.6 mm/sec, p<0.04), V (10.3±0.4 vs. 8.5±0.6 mm/sec, p<0.003)
and C (149±34 vs. 103±31 µm/sec, p<0.02). Conclusions: DRPs lower vascular resis-
tance and increase flow without causing vasodilation. The rise in flow is accompanied by
an increase in microvascular RBC velocity. Primary enhancement of microvascular perfu-
sion through modulation of the rheological properties of blood represents a promising,
novel therapeutic strategy for ischemic syndromes.
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Experimental data suggest that ACE inhibition results in an increased ventricular electri-
cal stability in acute myocardial infarction (AMI). As electrical stability is largely depen-
dent on ventricular repolarization, we sought to determine the impact of low-dose
intracoronary application of enalaprilat (EN) as an adjunct to direct PCI on the QT/RR
relationship in AMI.
Methods and Results: Twenty-two patients with AMI who underwent direct PCI (TIMI 3
flow) were randomized to EN (50µg) or saline (SA), given immediately after reperfusion.
On hospital admission a 24-hour-Holter-ECG was initiated. Slopes of the linear QT/RR
regression were determined for the time intervals before reperfusion and after reperfu-
sion. A total of 6 patients in the EN group and 6 patients in the SA group had valid Holter-
ECGs for QT analysis. Mean RR interval and QT interval were not significantly different
between the EN and the SA groups before and after PCI. There were also no significant
differences regarding QT/RR slopes between EN and SA groups before PCI. After PCI,
QT/RR slopes significantly decreased in the EN group, whereas there were no significant
alterations in the SA group.
Conclusion: Intracoronary EN therapy as an adjunct to direct PCI significantly
decreases QT/RR slopes, suggesting a normalization of the coupling between heart rate
and repolarization by improving electrical restitution. Thus, our findings offer new insights
into possible beneficial effects of ACE inhibition on electrical stability in AMI. 
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OBJECTIVES: We sought to evaluate the impact of abciximab, as adjunctive therapy to
routine infarct-related artery (IRA) stenting, on effectiveness of myocardial reperfusion.
BACKGROUND: The impact of abciximab on left ventricular (LV) volumes and function of
patients with acute myocardial infarction (AMI) undergoing IRA stenting is not yet
defined. METHODS: Four hundreds unselected patients with AMI were randomised 1:1
to IRA stenting alone or stenting plus abciximab. One- month gated 99m-Tc Sestamibi
SPECT had to be performed in a pre-specified subgroup of 250 patients to evaluate inf-
arct size and LV volumes. RESULTS:Out of the 250 patients planned for the scintigraphic
assessment, 8 died within the first month, 12 dropped out of the study protocol, 13 were
excluded because gated acquisition was precluded by arrhythmias or technical reasons,
and 35 had a previous myocardial infarction preventing the index infarct size evaluation.
Thus, 182 patients represent the final study group (99 patients were randomized to abcix-
imab therapy and 83 to stenting alone). There were no differences in the baseline clinical
and angiographic characteristics, and in discharge therapy between the 2 groups. In the
abciximab group infarct size was smaller than in stenting alone group (14.3±11.7 versus
19.1±13.0 %; p=0.01), resulting in smaller LV end-diastolic volume index (57.8±20.0 ver-
sus 64.6±20.8 mL/m2; p=0.03), and LV end-systolic volume index (31.7±17.4 versus
37.5±18.6 mL/m2; p=0.03). One-month LV ejection fraction was significantly higher in
patients randomized to abciximab, as compared to stenting alone (47.4±11.3 versus
43.9±11.7 %; p=0.04). Reinfarction within 30 days occurred in 3 (4%) of patients of the
stenting alone group as compared to none of the abciximab group (p=0.056). After
excluding the 3 patients who experienced a reinfarction, the beneficial effect of abciximab
on LV volumes and function still persists. CONCLUSIONS: The use of abciximab, as a
standard adjunctive therapy to IRA, leads to the reduction in infarct size, resulting in
smaller 1-month LV volumes and better LV function. The effect is not explained by the
lower reinfarction rate.
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Background: Despite fibrinolysis for ST-elevation MI (STEMI), a significant mortality
remains. A comprehensive analysis of cause of death and angiographic features could
provide important information for therapeutic decision-making and understanding patho-
pysiology.
Methods: 3683 patients from an angiographic database STEMI fibrinolysis trials were
analyzed. 180 deaths (4.9%) were observed. Angiographic features were measured by a
blinded core lab.
Results: Causes of death included: CHF/Shock (22%), Stroke/ICH (18%), dysrhythmia
(16%), cardiac rupture (13%), MI (12%), other cardiac (7%), hemorrhage (3%). Those
with cardiac death compared to survivors were less likely to have TIMI flow grade (TFG)
2-3 (p<0.001) and TIMI Myocardial Perfusion Grade (TMPG) 2-3 (p=.004); had higher
Corrected Frame Counts (CTFC, 68 vs.52, p<0.001), and were more likely to have 3 ves-
sel CAD (p=0.001) or thrombus (p=0.001). Among cardiac deaths, TFG 0-1, higher
CTFC, were associated with CHF/Shock (figure); TFG 0-1 and TMPG 0-1 were associ-
ated with dysrhythmia (figure) and cardiac rupture (p<0.05). There were no angiographic
correlates of CVA/hemorrhage.
Conclusions: Impairment of epicardial and myocardial perfusion were associated with
cardiovascular mortality. Angiographic features differed among causes of death. These
angiographic correlates with mortality may aid in understanding the limitations of reperfu-
sion therapy and the search for new modalities to reduce mortality in STEMI. 
